Description:
This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination
with hypomethylating agents (HMA) by evaluating MBG453 in combination with the HMA
azacitidine and the Bcl-2 inhibitor venetoclax. The primary purpose of Part 1 (Safety Run-in)
is to rule out excessive toxicity of MBG453, when administered in combination with
azacitidine and venetoclax. The primary purpose of the combined Part 1 and Part 2 (Safety
run-in and Expansion Part) is to evaluate efficacy of MBG453, when administered in
combination with azacitidine and venetoclax in adult patients with newly diagnosed AML, who
are not suitable for treatment with intensive chemotherapy.
Title
- Brief Title: A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy
- Official Title: A Phase II Multi-center, Single Arm, Safety and Efficacy Study of MBG453 in Combination With Azacitidine and Venetoclax for the Treatment of Acute Myeloid Leukemia (AML) in Adult Patients Unfit for Chemotherapy
Clinical Trial IDs
- ORG STUDY ID:
CMBG453C12201
- SECONDARY ID:
2019-000439-14
- NCT ID:
NCT04150029
Conditions
Interventions
Drug | Synonyms | Arms |
---|
MBG453 | Sabatolimab | MBG453+Venetoclax +Azacitidine |
Venetoclax | | MBG453+Venetoclax +Azacitidine |
Azacitidine | | MBG453+Venetoclax +Azacitidine |
Purpose
This trial will seek to extend the preliminary findings of efficacy of MBG453 in combination
with hypomethylating agents (HMA) by evaluating MBG453 in combination with the HMA
azacitidine and the Bcl-2 inhibitor venetoclax. The primary purpose of Part 1 (Safety Run-in)
is to rule out excessive toxicity of MBG453, when administered in combination with
azacitidine and venetoclax. The primary purpose of the combined Part 1 and Part 2 (Safety
run-in and Expansion Part) is to evaluate efficacy of MBG453, when administered in
combination with azacitidine and venetoclax in adult patients with newly diagnosed AML, who
are not suitable for treatment with intensive chemotherapy.
Trial Arms
Name | Type | Description | Interventions |
---|
MBG453+Venetoclax +Azacitidine | Experimental | Patients will receive MBG453 in combination with Venetoclax and Azacitidine | - MBG453
- Venetoclax
- Azacitidine
|
Eligibility Criteria
Inclusion Criteria:
1. Signed informed consent must be obtained prior to participation in the study.
2. Age ≥ 18 years at the date of signing the informed consent form (ICF)
3. Newly diagnosed with AML based on 2016 WHO classification (Arber et al 2016) and not
suitable for intensive chemotherapy defined as: age ≥75, ECOG performance Status 2 or
3, or any of the following comomorbitities: severe cardiac comorbities (including
congestive heart failure, LVEF ≤ 50%, chronic stable Angina) , pulmonary comorbidity
(DLCO ≤ 65% or FEVI ≤ 65%). moderate hepatic impairment (with total Bilirubin >1.5 to
3x ULN) , renal impairment (eGFR≥ 30 ml/min/1.73m^2 to 45 30 ml/min/1.73m^2), or other
comorbidity incompatible with intensive chemotherapy per Investigator assessement and
approved by the Novartis Medical monitor)
4. .Not planned for hematopoietic stem-cell transplantation (HSCT)
5. .Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 , 2 or 3
Exclusion Criteria:
1. Prior exposure to TIM-3 directed therapy
2. History of severe hypersensitivity reactions to any ingredient of study drug(s)
(azacitidine, venetoclax or MGB453) or monoclonal antibodies (mAbs) and/or their
excipients
3. Current use or use within 14 days prior to randomization of systemic, steroid therapy
(> 10 mg/day prednisone or equivalent) or any immunosuppressive therapy. Topical,
inhaled, nasal, ophthalmic steroids are allowed. Replacement therapy, steroids given
in the context of a transfusion are allowed and not considered a form of systemic
treatment.
4. Previous treatment at any time, with any of the following antineoplastic agents,
approved or investigational; checkpoint inhibitors, venetoclax and hypomethylating
agents (HMAs) such as decitabine or azacitidine.
5. Active autoimmune disease requiring systemic therapy (e.g.corticosteroids).
6. Live vaccine administered within 30 Days prior to randomization
Other protocol-defined Inclusion/Exclusion may apply.
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Incidence of dose limiting toxicities (Safety run-in patients only) |
Time Frame: | From Cycle 1 Day 8 to end of Cycle 2; Cycle =28 Days |
Safety Issue: | |
Description: | Assessment of tolerability of MBG in combination with venetoclax and azacitidine |
Secondary Outcome Measures
Measure: | Percentage of subjects achieving a complete remission (CR) or complete remission with incomplete hematologic blood count recovery (CRi) |
Time Frame: | every 12 weeks (starting at week 5) for up to 48 months from last patient first treatment |
Safety Issue: | |
Description: | Assessing the durability of complete remission (CR) or complete remission with incomplete hematologic blood count recovery (CRi) rate by determining the relapse free survival (RFS) in participants who achieve complete response (CR) |
Measure: | Time from date of first documented CR or CRi to the date of first documented relapse or death due to any cause |
Time Frame: | every 12 weeks (starting at week 5) for up to 48 months from last patient first treatment |
Safety Issue: | |
Description: | Time to relapse from CR/CRi or death (relapse free survival), whichever occurs first |
Measure: | Time from the date of the first documented CR to the date of first documented relapse or death due to any cause |
Time Frame: | every 12 weeks (starting at week 5) for up to 48 months from last patient first treatment |
Safety Issue: | |
Description: | Assessing the durability of complete remission (CR) by determining the Relapse Free Survival (RFS) in subjects who achieved CR, whichever occurs first |
Measure: | Time from start of treatment until death, relapse from CR, or treatment failure, whichever occurs first |
Time Frame: | every 12 weeks (starting at week 5) for up to 48 months from last patient first treatment |
Safety Issue: | |
Description: | Assessing event free survival (EFS). |
Measure: | Time from start of treatment to death due to any cause (overall survival) |
Time Frame: | date of start of treatment to date of death due to any reason (for up to 48 months from last patient first treatment) |
Safety Issue: | |
Description: | Time to death due to any cause to assess overall survival |
Measure: | Peak Serum Concentration (Cmax) MBG453 |
Time Frame: | Cycle 1 Day 8 (end of infusion) and Cycle 3 Day 8 (end of infusion), cycle = 28 days |
Safety Issue: | |
Description: | Maximal concentration of MBG453 |
Measure: | Trough Serum Concentration (Cmin) MBG453 |
Time Frame: | Day 8 of Cycle 1,2,3,6,9,12,18, 24 and through treatment completion, an average of 24 months |
Safety Issue: | |
Description: | Concentration of MBG453 prior to next dosing or after end of treatment |
Measure: | Trough Plasma Concentration (Cmin) Venetoclax |
Time Frame: | Day 8 of Cycle 1, 3 and 8 ; Cycle =28 days |
Safety Issue: | |
Description: | Trough concentration of venetoclax on treatment |
Measure: | Anti-drug Antibody (ADA) prevalence at baseline |
Time Frame: | prior to first dose of MGB453 on Cycle 1 Day 8 (cycle =28 Days) |
Safety Issue: | |
Description: | Immunogenicity to MBG453 prior to MBG453 exposure |
Measure: | ADA prevalence on-treatment |
Time Frame: | Throughout study until 150 day safety follow-up |
Safety Issue: | |
Description: | Immunogenicity to MBG453 on Treatment and after treatment |
Measure: | Percentage of MRD-negative subjects in the full study population and in subjects achieving CR or CRi |
Time Frame: | every 12 weeks (starting at week 5) for up to 48 months from last patient first treatment |
Safety Issue: | |
Description: | Rate of MRD-negative subjects |
Measure: | Rate of subjects who achieve transfusion independence from baseline and while on treatment. |
Time Frame: | from start of treatment up to 48 months from last patient first treatment |
Safety Issue: | |
Description: | Percentage of subjects who are not dependent on blood transfusions for more than 8 weeks will be determined and related to the total number of patients participating to report percentage |
Details
Phase: | Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Recruiting |
Lead Sponsor: | Novartis Pharmaceuticals |
Trial Keywords
- MBG453
- Venetoclax
- Azacitidine
- Phase 2
- AML
- Acute myeloid Leukemia
- Sabatolimab
Last Updated
May 18, 2021